I work with market-leading innovation companies to resolve their most challenging disputes through arbitration.






The Whiffenpoofs


Cooley Files Amicus Brief in Reproductive Rights Case Before SCOTUS

November 10, 2021

Cooley has filed an amicus brief in Whole Woman’s Health v. Jackson, one of the two cases currently before the Supreme Court challenging Texas Senate Bill 8 (SB 8), an unprecedented attempt to nullify the federal constitutional right to receive an abortion recognized in Roe v. Wade and Planned Parenthood v. Casey. Lawyers Kathleen Hartnett, Adam Gershenson, Julie Veroff, Patrick Hayden, Kelsey Spector, Marc Suskin, Rachel Thorn and Alessandra Vittoria Rafalson led the Cooley effort.

Read more

Related contacts

Kathleen R. Hartnett
Partner, San Francisco
Adam Gershenson
Partner, Boston
Patrick J. Hayden
Special Counsel, New York
Kelsey Spector
Associate, San Francisco
Marc Suskin
Partner, New York
Rachel Thorn
Partner, New York
Alessandra V. Rafalson
Associate, New York
Caroline Pignatelli
Special Counsel, New York
Laura Unga
Paralegal Specialist, Palo Alto

Related Practices & Industries

Otsuka Enters Worldwide Collaboration Agreement With Sunovion and Sumitomo Dainippon Pharma

October 13, 2021

Cooley advised Otsuka Pharmaceutical, a global healthcare company, on its worldwide collaboration and license agreement with biopharmaceutical company Sunovion Pharmaceuticals and parent company Sumitomo Dainippon Pharma for the joint development and commercialization of four novel candidate compounds. Lawyers Alison Freeman-Gleason and Brian Stalter led the Cooley team advising Otsuka.

Read more

Related contacts

Alison Freeman-Gleason
Of Counsel, Seattle
J. Brian Stalter
Special Counsel, New York
David Burns
Special Counsel, Washington, DC
Alexander Israel
Partner in Charge – Brussels, Brussels
Georgina Dietrich
Associate, Brussels
Jan Lang
Associate, Brussels
Marc Suskin
Partner, New York

Related Practices & Industries

Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech

April 3, 2020

Fate Therapeutics in its global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets. The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.

Under the terms of the agreement, Janssen will receive $50 million in cash and $50 million from the purchase by Johnson & Johnson Innovation  JJDC, Inc. of newly issued shares of the Company’s common stock at a price per share of $31.00. Janssen is also eligible to receive payments of up to  $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.

Related contacts

Lila Hope
Partner, Palo Alto
Rena Kaminsky
Special Counsel, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Amanda Pacheco
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Robert Eisenbach
Of Counsel, San Francisco
Marc Suskin
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC

Related Practices & Industries

Admissions & credentials

New York

Rankings & accolades

Chambers USA: International Arbitration: Counsel – Nationwide (2020 – 2023)

The Legal 500 US: Next Gen Partner for International Arbitration (2023)

Benchmark Litigation: Litigation Star – International Arbitration

Who's Who Legal: Arbitration – Future Leaders – Partners

the "go to" lawyer for tech arbitrations

Legal 500